Repeated intrathecal injection of IL‐18 BP effectively attenuated the tumor‐induced activation of NR2B and the subsequent Ca2+‐dependent signals as well as tumor‐induced bone cancer pain, suggesting that NFAT1/IL‐18 could regulate synaptic plasticity by interacting with NMDA receptors. The gene discussed is NFATC2; the disease is bone cancer.